Skip to main content
Log in

Treating Vasospasm with IV Milrinone: Relax (The Vessel) or Don’t Do It!

  • Letters to the editor
  • Published:
Neurocritical Care Aims and scope Submit manuscript

The Original Article was published on 11 July 2023

A Practice Guidance for Critical Care Management of SAH to this article was published on 09 May 2023

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Deem S, Diringer M, Livesay S, Treggiari MM. Hemodynamic management in the prevention and treatment of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2023. https://doi.org/10.1007/s12028-023-01738-w.

    Article  PubMed  Google Scholar 

  2. Castle-Kirszbaum M, Lai L, Maingard J, Asadi H, Danks RA, Goldschlager T, et al. Intravenous milrinone for treatment of delayed cerebral ischaemia following subarachnoid haemorrhage: a pooled systematic review. Neurosurg Rev. 2021;44:3107–24.

    Article  PubMed  Google Scholar 

  3. Joseph M, Ziadi S, Nates J, Dannenbaum M, Malkoff M. Increases in cardiac output can reverse flow deficits from vasospasm independent of blood pressure: a study using xenon computed tomographic measurement of cerebral blood flow. Neurosurgery. 2003;53:1044–51.

    Article  PubMed  Google Scholar 

  4. Fraticelli AT, Cholley BP, Losser M-R, Saint Maurice J-P, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008;39:893–8.

    Article  PubMed  Google Scholar 

  5. Lakhal K, Hivert A, Alexandre P-L, Fresco M, Robert-Edan V, Rodie-Talbere P-A, et al. Intravenous milrinone for cerebral vasospasm in subarachnoid hemorrhage: the MILRISPASM controlled before-after study. Neurocrit Care. 2021;35:669–79.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

No funding was required for this Letter to the Editor.

Author information

Authors and Affiliations

Authors

Contributions

KL drafting the manuscript. VRE: drafting the manuscript. The final manuscript was approved by all authors.

Corresponding author

Correspondence to Karim Lakhal.

Ethics declarations

Conflict of interest

Vincent Robert-Edan has no conflict of interest in connection with the work submitted. In addition, VRE received, during the past 3 years, travel fees from Pfizer (once, in 2020). Karim Lakhal has no conflict of interest in connection with the work submitted. In addition, KL received, during the past 3 years, congress registration from Pfizer (once in 2022) and both congress registration and travel fees from Pfizer (twice, in 2020) and Advanz Pharma/Correvio (twice, in 2020 and once in 2021).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The article is related to the response letter is available at https://doi.org/10.1007/s12028-023-01790-6. This article is related to the original work available at https://link.springer.com/article/10.1007/s12028-023-01738-w.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Robert-Edan, V., Lakhal, K. Treating Vasospasm with IV Milrinone: Relax (The Vessel) or Don’t Do It!. Neurocrit Care 39, 547–548 (2023). https://doi.org/10.1007/s12028-023-01789-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-023-01789-z

Navigation